Effect of nesiritide versus XXXX in the treatment of acute decompensated @entity712 .

@entity1 @entity712 @entity7604
The use of nesiritide in the improvement of @entity1 hemodynamics, decreased length of stay (LOS), and rehospitalization is discussed. Nesiritide is a useful agent for the treatment of the acutely decompensated @entity712 @entity1 . Previous trials suggest that the use of nesiritide results in improved outcomes as compared with other agents. To date, there are no data comparing nesiritide to @entity7604 in the treatment of the acutely decompensated @entity712 @entity1 . Fifty-five @entity1 admitted to the @entity712 service were identified retrospectively; 29 received nesiritide and 26 received @entity7604 . Baseline characteristics, hemodynamic data, and LOS data were collected. Primary outcomes were the overall LOS, intensive care LOS, and readmission within 30 days of discharge. Other outcomes included duration of vasoactive agents used, overall diuresis, and total cost of therapy. Baseline hemodynamic data were similar between groups. @entity1 in the @entity7604 group had an overall LOS of 8.2 days compared to 7 days in the nesiritide group (p = NS). LOS in the intensive care unit was 5.9 days in the @entity7604 group compared with 3.9 days in the nesiritide group (p = 0.007). Readmission at 30 days was 28% in the @entity7604 group compared with 16% in the nesiritide group (p = NS). Infusion time was shorter in the nesiritide group, 50 versus 117 hours (p = 0.001). Cost of therapy (cost of bed, supplies, and drug) was  398 less per @entity1 receiving nesiritide. The use of nesiritide led to improvement in @entity1 hemodynamics and resulted in a trend toward decreases in LOS and rehospitalization. Total cost of therapy was lower in the nesiritide group as compared to those @entity1 treated with @entity7604 .
